Resmetirom Poised to Become First NASH Treatment

(MedPage Today) -- Groundbreaking results from a phase III trial have set the stage for resmetirom to become the first drug approved for patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis. In the so-called MAESTRO-NASH study...
Source: MedPage Today Public Health - Category: American Health Source Type: news